Alzheimer's Disease

San Francisco, CA

46 Alzheimer's Disease Trials near San Francisco, CA

Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

NMRA-323511 for Agitation in Alzheimer's Disease

Walnut Creek, California
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90

96 Participants Needed

Financial Incentives for Alzheimer's Prevention

Martinez, California
This single-blind, three-arm, randomized, controlled trial will assess the impact of messages and financial incentives on the enrollment of demographically diverse individuals to the Alzheimer Prevention Trials (APT) Webstudy. The APT Webstudy is a novel, online registry that employs quarterly cognitive testing using validated platforms. The APT Webstudy implements fully remote assessments, coordinated by the Alzheimer's Therapeutic Research Institute (ATRI) under USC IRB #HS-17-00746. The purpose of the current study is to test whether we can increase enrollment of diverse individuals into the registry. To do this, we will work with Contra Costa Regional Medical Center (CCRMC), the county public hospital and its affiliated health centers in Contra Costa County, California, to test whether sending messages with and without financial incentives to patients who receive primary care with the health system can increase enrollment to the APT Webstudy. The investigators hypothesize that 1) a certain small financial incentive and an award opportunity based incentive (or a drawing with a prize) will increase enrollment rates of CCHS members into the APT Webstudy relative to the control group. The investigators further hypothesize that the award opportunity incentive will increase the enrollment rate of CCRMC patients into the APT Webstudy more than a certain financial incentive with the same expected value.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50+

48000 Participants Needed

KarXT + KarX-EC for Alzheimer's Disease

Palo Alto, California
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:60 - 85

586 Participants Needed

CT1812 for Early Alzheimer's Disease

Palo Alto, California
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85

540 Participants Needed

Bepranemab for Alzheimer's Disease

Palo Alto, California
This trial is testing bepranemab, a new medication, to see if it can help people with early-stage Alzheimer's disease. The study focuses on individuals who are just starting to show symptoms or have mild symptoms. Bepranemab works by removing harmful proteins from the brain that are linked to Alzheimer's.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 80

466 Participants Needed

Sleep Therapies for Alzheimer's Disease

Palo Alto, California
Recent findings suggest that sleep disruption may contribute to the generation and maintenance of neuropsychiatric symptoms including anxiety, depression, agitation, irritation, and apathy while treating sleep disruption reduces these symptoms. Impairments in the neural systems that support emotion regulation may represent one causal mechanism mediating the relationship between sleep and emotional distress. However, this model has not yet been formally tested within a sample of individuals with or at risk for developing Alzheimer's Disease (AD) This proposal aims to test a mechanistic model in which sleep disturbance contributes to neuropsychiatric symptoms through impairments in fronto-limbic emotion regulation function in a sample of individuals at risk for developing, or at an early stage of AD. This study seeks to delineate the causal association between sleep disruption, fronto-limbic emotion regulation brain function, and neuropsychiatric symptoms. These aims will be achieved through a mechanistic, randomized 2-arm controlled trial design. 150 adults experiencing sleep disturbances and who also have cognitive impairment with the presence of at least mild neuropsychiatric symptoms will be randomized to receive either a sleep manipulation (Cognitive Behavioral Therapy for Insomnia CBT-I; n=75) or an active control (n=75). CBT-I improves sleep patterns through a combination of sleep restriction, stimulus control, mindfulness training, cognitive therapy targeting dysfunctional beliefs about sleep, and sleep hygiene education. Neuropsychiatric symptoms, fronto-limbic functioning, and sleep disruption will be assessed at baseline and at the end of the sleep manipulation through functional Magnetic Resonance Imaging (fMRI), clinical interviews, PSG recordings, and self-report questionnaires. Neuropsychiatric symptoms (anxiety and depression) and sleep disturbance (actigraphy, Insomnia Severity Index, and sleep diaries) will be assayed at baseline and each week throughout the sleep manipulation to assess week-to-week changes following an increasing number of CBT-I sessions. Wristwatch actigraphy will be acquired from baseline to the end of the sleep manipulation at week 11. Neuropsychiatric symptoms and sleep will be assessed again at six months post-manipulation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 90

150 Participants Needed

Vagus Nerve Stimulation for Aging

Stanford, California
The aim of this study is to determine whether non-invasive vagus nerve stimulation enhances memory formation in cognitively healthy older adults and whether the effects of stimulation depend on gut and brain health.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

150 Participants Needed

Bumetanide for Alzheimer's Disease

Stanford, California
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets. Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease. Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 85

40 Participants Needed

VR Audiovisual Stimulation for Alzheimer's Disease

Portola Valley, California
This is a single-blind, sham-controlled, clinical trial that aims to evaluate the safety, tolerability, and feasibility of delivering audiovisual stimulation via a Virtual Reality (VR) headset to people cognitively impaired due to Alzheimer's and cognitively unimpaired people.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:50 - 90

60 Participants Needed

JNJ-63733657 for Alzheimer's Disease

Palo Alto, California
This trial is testing a new drug called JNJ-63733657 to see if it can help slow down the worsening of symptoms in patients with Alzheimer's disease. The goal is to see if the drug can help maintain brain function and daily living skills better.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 80

523 Participants Needed

Escitalopram for Agitation in Alzheimer's Disease

Stanford, California
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

187 Participants Needed

Water-Based Exercise + Cognitive Training for Mild Cognitive Impairment

Palo Alto, California
This four-year study will evaluate the efficacy of an exercise training augmentation for cognitive training intervention to improve memory performance in Veterans with a diagnosis of amnestic Mild Cognitive Impairment (aMCI). This is a two-phased trial: 1) an exercise phase and 2) a cognitive training program. The exercise phase will be an aquatic based exercise program. A combination of exercise and cognitive training programs designed for persons without cognitive impairment have significantly improved memory more than other single intervention groups (exercise only, cognitive training only) and given the success of combination training programs with healthy older adults, it is important to adapt these programs for persons beginning to exhibit clinically significant memory problems, such as those with aMCI.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:50 - 90

121 Participants Needed

KarXT + KarX-EC for Agitation in Alzheimer's Disease

Napa, California
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

352 Participants Needed

Acoramidis for Amyloidosis

San Francisco, California
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

582 Participants Needed

Rideshare Services for Alzheimer's Disease

San Leandro, California
The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services. he main question it aims to answer is: Do D2D rideshare services reduce missed medical appointment rates compared to C2C rideshare services?
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:60+

120 Participants Needed

DPd for Amyloidosis

Palo Alto, California
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

15 Participants Needed

Why Other Patients Applied

"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

EK
Mild Cognitive Impairment PatientAge: 72

"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

OF
Alzheimer's Disease PatientAge: 65

"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

WU
Healthy Volunteer PatientAge: 76

"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

VL
Alzheimer's PatientAge: 71

"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

AH
Dementia PatientAge: 64
12

Know someone looking for new options? Spread the word

Match to a Trial